Recently, sotorasib was approved by the FDA for KRAS G12C mutation in non-small cell lung cancer, but drugs for the treatment (Additional file 2) of other KRAS mutations are still not available. This evidence concerns the gene KRAS and non-small cell lung carcinoma.